Polatuzumab vedotin + Rituximab + Bendamustine (Pola-BR), 6 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-POLATUZUMAB-VEDOTIN DRUG-RITUXIMAB DRUG-BENDAMUSTINE |
|---|
| ID | REG-POLA-R-BENDAMUSTINE |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Notes
GO29365 randomized phase 1b/2 (Sehn 2020): in r/r DLBCL ineligible for autoSCT, Pola-BR vs BR alone showed CR 40% vs 18%, mPFS 9.5 vs 3.7 mo, mOS 12.4 vs 4.7 mo. Approved 2L+ for transplant-ineligible r/r DLBCL. Active CD20 + CD79b expression both required (post-CD19/CD20 CAR-T patients — verify CD20 retention by repeat IHC). Bendamustine myelosuppression cumulative — GCSF prophylaxis recommended.
Used By
Indication
IND-DLBCL-2L-POLA-R-BENDAMUSTINE- IND-DLBCL-2L-POLA-R-BENDAMUSTINE